Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 80.38
2
Poor long term growth as Net Sales has grown by an annual rate of 3.41% and Operating profit at 10.88% over the last 5 years
3
The company declared positive results in Mar'25 after very negative results in Dec'24
4
With ROE of 6.67%, it has a very attractive valuation with a 0.71 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 93,215 Million (Small Cap)
11.00
NA
0.00%
0.07
7.65%
0.68
Revenue and Profits:
Net Sales:
30,229 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,100 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.34%
0%
-4.34%
6 Months
0.88%
0%
0.88%
1 Year
1.22%
0%
1.22%
2 Years
-18.14%
0%
-18.14%
3 Years
-14.2%
0%
-14.2%
4 Years
-16.45%
0%
-16.45%
5 Years
-22.26%
0%
-22.26%
KYORIN Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.41%
EBIT Growth (5y)
10.88%
EBIT to Interest (avg)
80.02
Debt to EBITDA (avg)
0.31
Net Debt to Equity (avg)
0.08
Sales to Capital Employed (avg)
0.79
Tax Ratio
28.85%
Dividend Payout Ratio
32.88%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
5.21%
ROE (avg)
4.44%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.71
EV to EBIT
8.59
EV to EBITDA
6.28
EV to Capital Employed
0.73
EV to Sales
0.83
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
8.50%
ROE (Latest)
6.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.11%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
30,229.00
40,801.00
-25.91%
Operating Profit (PBDIT) excl Other Income
3,507.00
10,625.00
-66.99%
Interest
64.00
70.00
-8.57%
Exceptional Items
100.00
-204.00
149.02%
Consolidate Net Profit
2,100.00
6,647.00
-68.41%
Operating Profit Margin (Excl OI)
78.30%
231.60%
-15.33%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -25.91% vs 19.49% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -68.41% vs 461.40% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
130,087.00
119,532.00
8.83%
Operating Profit (PBDIT) excl Other Income
17,150.00
10,516.00
63.08%
Interest
173.00
66.00
162.12%
Exceptional Items
-319.00
-788.00
59.52%
Consolidate Net Profit
9,086.00
5,475.00
65.95%
Operating Profit Margin (Excl OI)
96.50%
52.10%
4.44%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 8.83% vs 5.53% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 65.95% vs 15.92% in Mar 2024
About KYORIN Pharmaceutical Co., Ltd. 
KYORIN Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






